Polypyrimidine tract binding protein 1 promotes lymphatic metastasis and proliferation of bladder cancer via alternative splicing of MEIS2 and PKM

Xie, Ruihui; Chen, Xu; Chen, Ziyue; Huang, Ming; Dong, Wen; Gu, Peng; Zhang, Jingtong; Zhou, Qianghua; Wang, Dong; Han, Jing; Wang, Xisheng; Li, Hui; Huang, Jian; Lin, Tianxin

doi:10.1016/j.canlet.2019.01.041

Cited by 77 publications

(73 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MEIS2 promoted cell invasion and migration in colorectal cancer, 30 prostate cancer, 31 bladder cancer. 32 MEIS2 had the highest correlation with L-OHP resistance in colorectal cancer. 33 MEIS2 was also critical to MN1-induced leukemia, by regulating self-renewal, proliferation, disease progression and impairment of differentiation.…”

Section: Discussionmentioning

confidence: 93%

<p>ZFAS1 Promotes Cisplatin Resistance via Suppressing miR-421 Expression in Oral Squamous Cell Carcinoma</p>

Wang¹,

Hao²,

Wang³

et al. 2020

CMAR

View full text Add to dashboard Cite

Oral squamous cell carcinoma (OSCC), with high incidence and mortality, represents one of the main reasons for head and neck malignant tumors. We want to investigate the effect of ZFAS1 on DDP resistance in oral squamous cell carcinoma. Methods: The proliferation and migration of cells was detected by CCK-8 and Transwell assay. The apoptosis was measured by flow cytometry and Western blot. The interaction of ZFAS1, miR-421, and MEIS2 was verified by luciferase reporter assay. The role of ZFAS1 in DDP resistance in vivo was tested by the nude mice model. The expression of ZFAS1 in exosomes from cisplatin-resistant patients was also determined. Results: ZFAS1 overexpression improved OSCC cell growth and inhibited OSCC cell susceptibility to DDP. In addition, the silencing of ZFAS1 promoted DDP-induced apoptosis. ZFAS1 directly bound to miR-421, which was verified by luciferase reporter assay. Inhibition of miR-421 reversed the effect of si-ZFAS1, which promoted the cell viability and decreased the sensitivity of DDP in DDP-resistant cells. The in vivo experiment showed the role of ZFAS1 in increasing the DDP resistance in OSCC tumor. Importantly, this study also showed upregulated ZFAS1 in serum exosomes derived from cisplatin-resistant patients. Conclusion: ZFAS1 promotes chemoresistance of oral squamous cell carcinoma to cisplatin and might become a latent therapeutic target for treating OSCC.

show abstract

Section: Discussionmentioning

confidence: 93%

<p>ZFAS1 Promotes Cisplatin Resistance via Suppressing miR-421 Expression in Oral Squamous Cell Carcinoma</p>

Wang¹,

Hao²,

Wang³

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…The in vivo metastasis assay was performed as previously described. 24,25 All procedures involving animals were approved by the Institute Animal Care and Use Committee of Sun Yat-sen University. Male BALB/c nude mice (4-6 weeks old) were purchased from the Experimental Animal Center of Sun Yat-sen University and housed in specific pathogen-free (SPF) barrier facilities.…”

Section: In Vivo Metastasis and Tumorigenesis Experimentsmentioning

confidence: 99%

The metastatic promoter DEPDC1B induces epithelial‐mesenchymal transition and promotes prostate cancer cell proliferation via Rac1‐PAK1 signaling

Wang

Peng

et al. 2020

Clinical & Translational Med

Self Cite

View full text Add to dashboard Cite

Metastasis is the major cause of prostate cancer (PCa)-related mortality. Epithelial-mesenchymal transition (EMT) is a vital characteristic feature that empowers cancer cells to adapt and survive at the beginning of metastasis. Therefore, it is essential to identify the regulatory mechanism of EMT in metastatic prostate cancer (mPCa) and to develop a novel therapy to block PCa metastasis. Here, we discovered a novel PCa metastasis oncogene, DEP domain containing 1B (DEPDC1B), which was positively correlated with the metastasis status, high Gleason score, advanced tumor stage, and poor prognosis. Functional assays revealed that DEPDC1B enhanced the migration, invasion, and proliferation of PCa cells in vitro and promoted tumor metastasis and growth in vivo. Mechanistic investigations clarified that DEPDC1B induced EMT and enhanced proliferation by binding to Rac1 and enhancing the Rac1-PAK1 pathway. This DEPDC1Bmediated oncogenic effect was reversed by a Rac1-GTP inhibitor or Rac1

show abstract

“…In prostate cancer, androgen receptor spliced variants (AR‐Vs) have been implicated in the carcinogenesis of metastatic prostate cancer, which contribute to resistance to both anti‐androgen therapy and radiotherapy 85 . In bladder cancer, Xie et al 86 illustrated that PTBP1 promotes bladder cancer lymph node metastasis and cell proliferation via an alternative splicing dependent mechanism and that PTBP1 could be a novel prognostic marker and therapeutic target. In renal cell carcinoma, SF3B3 modulates EZH2 alternative splicing to promote carcinogenesis, and SF3B3 could be a potential prognostic factor and therapeutic target in renal cell carcinoma 87 …”

Section: Discussionmentioning

confidence: 99%

Roles of N⁶‐methyladenosine (m⁶A) RNA modifications in urological cancers

Wang

Xie

Ying

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Epigenetics has long been a hot topic in the field of scientific research. The scope of epigenetics usually includes chromatin remodelling, DNA methylation, histone modifications, non‐coding RNAs and RNA modifications. In recent years, RNA modifications have emerged as important regulators in a variety of physiological processes and in disease progression, especially in human cancers. Among the various RNA modifications, m6A is the most common. The function of m6A modifications is mainly regulated by 3 types of proteins: m6A methyltransferases (writers), m6A demethylases (erasers) and m6A‐binding proteins (readers). In this review, we focus on RNA m6A modification and its relationship with urological cancers, particularly focusing on its roles and potential clinical applications.

show abstract

Polypyrimidine tract binding protein 1 promotes lymphatic metastasis and proliferation of bladder cancer via alternative splicing of MEIS2 and PKM

Cited by 77 publications

References 68 publications

<p>ZFAS1 Promotes Cisplatin Resistance via Suppressing miR-421 Expression in Oral Squamous Cell Carcinoma</p>

<p>ZFAS1 Promotes Cisplatin Resistance via Suppressing miR-421 Expression in Oral Squamous Cell Carcinoma</p>

The metastatic promoter DEPDC1B induces epithelial‐mesenchymal transition and promotes prostate cancer cell proliferation via Rac1‐PAK1 signaling

Roles of N⁶‐methyladenosine (m⁶A) RNA modifications in urological cancers

Contact Info

Product

Resources

About

Polypyrimidine tract binding protein 1 promotes lymphatic metastasis and proliferation of bladder cancer via alternative splicing of MEIS2 and PKM

Cited by 77 publications

References 68 publications

<p>ZFAS1 Promotes Cisplatin Resistance via Suppressing miR-421 Expression in Oral Squamous Cell Carcinoma</p>

<p>ZFAS1 Promotes Cisplatin Resistance via Suppressing miR-421 Expression in Oral Squamous Cell Carcinoma</p>

The metastatic promoter DEPDC1B induces epithelial‐mesenchymal transition and promotes prostate cancer cell proliferation via Rac1‐PAK1 signaling

Roles of N6‐methyladenosine (m6A) RNA modifications in urological cancers

Contact Info

Product

Resources

About

Roles of N⁶‐methyladenosine (m⁶A) RNA modifications in urological cancers